Bristol-Myers Squibb has
announced the listing of Yervoy
on the Pharmaceutical Benefits
Scheme from tomorrow 01 Aug
for the treatment of patients with
malignant melanoma (unresectable
stage III or stage IV).
The company says Yervoy is one
of the most significant treatment
advances for advanced melanoma
in many years, and is the first
therapy to show a long-term
survival benefit for some patients.
Advanced melanoma claims
the lives of approximately 1,500
Australians each year.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 13
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.